[March 05, 2013]

Research and Markets: PharmaPoint: HIV - United Kingdom Drug Forecast and Market Analysis to 2022

Research and Markets (http://www.researchandmarkets.com/research/knsqzv/pharmapoint_hiv) has announced the addition of GlobalData's new report "PharmaPoint: HIV - United Kingdom Drug Forecast and Market Analysis to 2022" to their offering.

GlobalData has released its new Country report, PharmaPoint: HIV - United Kingdom Drug Forecast and Market Analysis to 2022. Human Immunodeficiency Virus (HIV), the causative agent of AIDS, has claimed millions of lives since its emergence. However, the advent of antiretroviral therapy (ART) has transformed the face of HIV/AIDS from a deadly disease to a manageable chronic condition for most infected individuals. Antiretroviral treatment not only reduces the viral load and reconstitutes immune function, bt also decreases infection incidence rates by limiting viral transmission. The treatment algorithm in HIV has characteristically involved multiple drug regimens designed to tackle the virus on different levels. In the recent past, simplified dosing regimens through the emergence of single tablet regimens (STRs) or fixed dose combination (FDC) therapies have become increasingly popular amongst physicians and patients alike by increasing clinical efficacy thresholds and enabling patient compliance.

As in the US, several STRs are expected to be released during the forecast period, overthrowing Atripla from its position of prominence. As a whole, the combined market share of STRs will be affected by key patent expiries, such as those of BMS' Sustiva, a key component of Atripla. Combined with healthcare budget restrictions imposed by the general financial situation in Europe, this might lead to a drastic drop in Atripla sales, with newer STRs facing a higher barrier to entry into the UK market.

Scope

- Overview of the United Kingdom including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

- Sales forecast for the top drugs in the United Kingdom from 2012-2022.

- Analysis of the impact of key events as well the drivers and restraints affecting the United Kingdom HIV market.

For more information visit http://www.researchandmarkets.com/research/knsqzv/pharmapoint_hiv

Source (News - Alert): GlobalData

[ InfoTech Spotlight's Homepage ]